Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...
Strongest, most consistent signal of benefit with walking, but only in nonmetastatic CRC ...